Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay

Abstract Prostate cancer remains the most common non-cutaneous malignancy among men in the United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched pre-operative and post-operative serum samples fro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shiqin Liu, Fernando Garcia-Marques, Chiyuan Amy Zhang, Jordan John Lee, Rosalie Nolley, Michelle Shen, En-Chi Hsu, Merve Aslan, Kashyap Koul, Sharon J. Pitteri, James D. Brooks, Tanya Stoyanova
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c6bfe0a2ff6e4c97bafc3c2d9739e9ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6bfe0a2ff6e4c97bafc3c2d9739e9ab
record_format	dspace
spelling	oai:doaj.org-article:c6bfe0a2ff6e4c97bafc3c2d9739e9ab2021-12-02T14:37:39ZDiscovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay10.1038/s41598-021-87155-52045-2322https://doaj.org/article/c6bfe0a2ff6e4c97bafc3c2d9739e9ab2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87155-5https://doaj.org/toc/2045-2322Abstract Prostate cancer remains the most common non-cutaneous malignancy among men in the United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched pre-operative and post-operative serum samples from ten men with high-grade and high-volume prostate cancer. Our study identified six (CASP8, MSLN, FGFBP1, ICOSLG, TIE2 and S100A4) out of 174 proteins that were significantly decreased after radical prostatectomy. High levels of CASP8 were detected in pre-operative serum samples when compared to post-operative serum samples and serum samples from patients with benign prostate hyperplasia (BPH). By immunohistochemistry, CASP8 protein was expressed at higher levels in prostate cancer tissues compared to non-cancerous and BPH tissues. Likewise, CASP8 mRNA expression was significantly upregulated in prostate cancer when compared to benign prostate tissues in four independent clinical datasets. In addition, mRNA levels of CASP8 were higher in patients with recurrent prostate cancer when compared to patients with non-recurrent prostate cancer and high expression of CASP8 was associated with worse disease-free survival and overall survival in renal cancer. Together, our results suggest that CASP8 may potentially serve as a biomarker for high-risk prostate cancer and possibly renal cancer.Shiqin LiuFernando Garcia-MarquesChiyuan Amy ZhangJordan John LeeRosalie NolleyMichelle ShenEn-Chi HsuMerve AslanKashyap KoulSharon J. PitteriJames D. BrooksTanya StoyanovaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shiqin Liu Fernando Garcia-Marques Chiyuan Amy Zhang Jordan John Lee Rosalie Nolley Michelle Shen En-Chi Hsu Merve Aslan Kashyap Koul Sharon J. Pitteri James D. Brooks Tanya Stoyanova Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
description	Abstract Prostate cancer remains the most common non-cutaneous malignancy among men in the United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched pre-operative and post-operative serum samples from ten men with high-grade and high-volume prostate cancer. Our study identified six (CASP8, MSLN, FGFBP1, ICOSLG, TIE2 and S100A4) out of 174 proteins that were significantly decreased after radical prostatectomy. High levels of CASP8 were detected in pre-operative serum samples when compared to post-operative serum samples and serum samples from patients with benign prostate hyperplasia (BPH). By immunohistochemistry, CASP8 protein was expressed at higher levels in prostate cancer tissues compared to non-cancerous and BPH tissues. Likewise, CASP8 mRNA expression was significantly upregulated in prostate cancer when compared to benign prostate tissues in four independent clinical datasets. In addition, mRNA levels of CASP8 were higher in patients with recurrent prostate cancer when compared to patients with non-recurrent prostate cancer and high expression of CASP8 was associated with worse disease-free survival and overall survival in renal cancer. Together, our results suggest that CASP8 may potentially serve as a biomarker for high-risk prostate cancer and possibly renal cancer.
format	article
author	Shiqin Liu Fernando Garcia-Marques Chiyuan Amy Zhang Jordan John Lee Rosalie Nolley Michelle Shen En-Chi Hsu Merve Aslan Kashyap Koul Sharon J. Pitteri James D. Brooks Tanya Stoyanova
author_facet	Shiqin Liu Fernando Garcia-Marques Chiyuan Amy Zhang Jordan John Lee Rosalie Nolley Michelle Shen En-Chi Hsu Merve Aslan Kashyap Koul Sharon J. Pitteri James D. Brooks Tanya Stoyanova
author_sort	Shiqin Liu
title	Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
title_short	Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
title_full	Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
title_fullStr	Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
title_full_unstemmed	Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
title_sort	discovery of casp8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c6bfe0a2ff6e4c97bafc3c2d9739e9ab
work_keys_str_mv	AT shiqinliu discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT fernandogarciamarques discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT chiyuanamyzhang discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT jordanjohnlee discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT rosalienolley discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT michelleshen discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT enchihsu discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT merveaslan discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT kashyapkoul discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT sharonjpitteri discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT jamesdbrooks discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay AT tanyastoyanova discoveryofcasp8asapotentialbiomarkerforhighriskprostatecancerthroughahighmultipleximmunoassay
_version_	1718391034556186624

Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay

Ejemplares similares